Brokerages Set Hikma Pharmaceuticals PLC (LON:HIK) Price Target at GBX 2,250

Hikma Pharmaceuticals PLC (LON:HIK) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is GBX 2,325 ($30.57).

HIK has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 2,750 ($36.16) price target on shares of Hikma Pharmaceuticals in a report on Tuesday, June 18th. Berenberg Bank raised shares of Hikma Pharmaceuticals to a “buy” rating and increased their target price for the company from GBX 2,100 ($27.61) to GBX 2,400 ($31.56) in a report on Monday, September 2nd.

Hikma Pharmaceuticals Trading Down 1.8 %

LON:HIK opened at GBX 1,956 ($25.72) on Friday. The stock has a market capitalization of £4.34 billion, a price-to-earnings ratio of 3,009.23, a PEG ratio of 2.38 and a beta of 0.41. Hikma Pharmaceuticals has a 1 year low of GBX 1,711 ($22.50) and a 1 year high of GBX 2,165 ($28.47). The stock has a fifty day moving average price of GBX 1,923.37 and a two-hundred day moving average price of GBX 1,921.04. The company has a debt-to-equity ratio of 55.48, a quick ratio of 1.27 and a current ratio of 1.66.

Hikma Pharmaceuticals Cuts Dividend

The firm also recently disclosed a dividend, which will be paid on Friday, September 20th. Investors of record on Thursday, August 15th will be paid a $0.32 dividend. The ex-dividend date is Thursday, August 15th. This represents a yield of 1.37%. Hikma Pharmaceuticals’s payout ratio is 9,538.46%.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.